fbpx
Menu

Tetraphase Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update 

Share

XERAVATM (eravacycline) Now Available to Hospitals in the United States

During the third quarter of 2018, we reached our most significant milestones as a company to date with the regulatory approvals of XERAVA for the treatment of complicated intra-abdominal infections (cIAI) in both the U.S. and Europe, followed by the commercial launch of XERAVA in the U.S. in October.

We are thrilled to have accomplished these extraordinary achievements and to have made this important new antibiotic treatment available to patients in need. XERAVA is now available for use in hospitals and healthcare institutions for the treatment of a range of patients with empiric and Mr. Macdonald added, We are also pleased to have entered into a loan agreement for up to $75 million, the first $30 million tranche of which extends our cash runway into the second quarter of 2020 and provides us with additional flexibility to support a strong launch of XERAVA in the U.S. Beyond XERAVA, we look forward to milestones for our earlier-stage programs, including completion of our Phase 1 multiple ascending-dose study for oral TP-271, in development to target respiratory infections, and initiation of a bronchopulmonary disposition study for TP-6076, targeted against Acinetobacter baumannii and other MDR pathogens. As a commercial company with a focus on delivering XERAVA to patients in need, we are also …

[Read on via official release]

Source: US SEC
View full document:
EX-991_of_8-K_for_TETRAPHASE_PHARMACEUTICALS_INC__8-K-11-08-2018